8-K current report · filed Nov 10, 2026

Cullinan Therapeutics, Inc. (CGEM) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1CGEM overview

Short answer

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.

Cullinan Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Cash and investments $313.8M at September 30, supporting operations into 2029 under the current plan
  • Zipalertinib first-line NDA submission underway, with Cullinan eligible for $100M approval milestone and 50/50 U.S. profit share
  • Zipalertinib monotherapy NDA remains under review, with FDA action date February 27, 2027
  • Velinotamig SLE data showed complete renal response in 4 of 7 patients with elevated baseline proteinuria
  • Third-quarter net loss $49.4M, or $0.74 per share, versus $50.6M, or $0.77, in 2025

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cullinan Therapeutics, Inc. 8-K filings

Get the next CGEM 8-K as it lands

Follow CGEM for push alerts, or ask the research agent what this filing means.